Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsIndia

COVID-19 | Hetero, Cipla get nod to manufacture, market antiviral drug remdesivir

Remdesivir, administered in the form of injection, should be given at a dose of 200 mg on day one followed by 100 mg daily for five days.

June 22, 2020 / 10:27 PM IST

India's Drug Regulator on June 20 gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients, official sources said. This comes a day after the Drug Controller General of India (DCGI), considering the emergency and unmet need for medicines in light of the coronavirus outbreak, granted domestic firm Glenmark Pharmaceuticals the permission to manufacture and market favipiravir for "restricted emergency use" in mild to moderate cases.

"The approval to Hetero and Cipla was given on Saturday," a source said.

Hetero’s generic version of remdesivir will be marketed under the brand name ‘COVIFOR’ in India, as per the company's press release.

Written informed consent of each patient is required before the use of remdesivir and results of additional clinical trials, active post-marketing surveillance data and reporting of serious adverse events have to be submitted.